Company intelligence / Profile preview

Suzhou Cure Genetics

Suzhou, Jiangsu, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

CureGenetics is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on advancing gene editing and cell therapy technologies. The company utilizes its proprietary VELP (Virus-like Editing Lipoprotein) delivery system and CRISPR/Cas platforms to develop transformative treatments for cancer and genetic diseases. Their pipeline includes CAR-T therapies for multiple myeloma and in vivo gene editing programs for hematological disorders. CureGenetics aims to bridge the gap between cutting-edge genomic research and clinical application through robust R&D and strategic partnerships.

Therapeutic areas: OncologyInfectious DiseasesHematology
Modalities: CAR-T cell therapyCRISPR-based therapyLipid nanoparticle delivery therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on Suzhou Cure Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Cure Genetics.

Explore the full profile